Ramucirumab

Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor.


Cat. No.: EX-A7004	Purity: >98%

	Chemical structure of Ramucirumab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	650	In-stock
10mg	950	In-stock
25mg	get quote	In-stock
50mg	get quote	In-stock
100mg	get quote	In-stock
200mg	get quote	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	947687-13-0
Purity	>98%
Mol Weight	143609.63
Color	colorless to light yellow (sol
State	liquid
Storage	Store at 4℃, do not freeze
Shipping	Shipping with dry ice.

Reference:	[1]. Fala L. Cyramza (Ramucirumab) Approved for the Treatment of Advanced Gastric Cancer and Metastatic Non-Small-Cell Lung Cancer. Am Health Drug Benefits. 2015 Mar;8(Spec Feature):49-53. [2]. Oholendt AL, et al. Ramucirumab: A New Therapy for Advanced Gastric Cancer. J Adv Pract Oncol. 2015 Jan-Feb;6(1):71-5. [3]. Lowery CD, et al. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy. Oncotarget. 2019 Sep 17;10(53):5523-5533.
CoA	CoA of Ramucirumab


		Search